Lupus Nephritis: A Different Disease in European Patients?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10313550" target="_blank" >RIV/00216208:11110/15:10313550 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10313550

Výsledek na webu

<a href="http://www.karger.com/Article/Pdf/438844" target="_blank" >http://www.karger.com/Article/Pdf/438844</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000438844" target="_blank" >10.1159/000438844</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lupus Nephritis: A Different Disease in European Patients?

Popis výsledku v původním jazyce

Background: Lupus nephritis (LN) is still associated with significant mortality and substantial risk of progression to endstage renal failure. Its outcome is related to the class and severity of LN and response to treatment, and it is poorer in patientswith renal relapses. Ethnicity has a relatively welldefined impact on the outcome of the patients and their response to treatment and must always be taken into consideration in treatment decisions. Summary: In this article, we provide a review of the impact of ethnicity on the prevalence of systemic lupus erythematosus (SLE), the proportion of patients with SLE developing LN, outcomes of SLE and LN and response of LN to treatment. In European patients, the prevalence of SLE and the proportion of SLE patients with LN are lower and the outcome of LN is better than in nonwhite populations. European patients may respond better to some modes of treatment [e.g. cyclophosphamide (CYC) or rituximab] and may be less frequently refractory to trea

Název v anglickém jazyce

Lupus Nephritis: A Different Disease in European Patients?

Popis výsledku anglicky

Background: Lupus nephritis (LN) is still associated with significant mortality and substantial risk of progression to endstage renal failure. Its outcome is related to the class and severity of LN and response to treatment, and it is poorer in patientswith renal relapses. Ethnicity has a relatively welldefined impact on the outcome of the patients and their response to treatment and must always be taken into consideration in treatment decisions. Summary: In this article, we provide a review of the impact of ethnicity on the prevalence of systemic lupus erythematosus (SLE), the proportion of patients with SLE developing LN, outcomes of SLE and LN and response of LN to treatment. In European patients, the prevalence of SLE and the proportion of SLE patients with LN are lower and the outcome of LN is better than in nonwhite populations. European patients may respond better to some modes of treatment [e.g. cyclophosphamide (CYC) or rituximab] and may be less frequently refractory to trea

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Kidney Diseases

ISSN

2296-9381

e-ISSN

—

Svazek periodika

1

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

9

Strana od-do

110-118

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—